KBC Group
MDGL icon

KBC Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

KBC Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
484
+70
+17% +$33.4K ﹤0.01% 906
2025
Q4 		$241K Hold
414
– – ﹤0.01% 849
2025
Q3 		$190K Hold
414
– – ﹤0.01% 926
2025
Q2 		$125K Sell
414
-208
-33% -$62K ﹤0.01% 1079
2025
Q1 		$206K Buy
622
+13
+2% +$4.27K ﹤0.01% 1055
2024
Q4 		$188K Buy
609
+258
+74% +$72.6K ﹤0.01% 1164
2024
Q3 		$74K Hold
351
– – ﹤0.01% 1485
2024
Q2 		$98K Buy
351
+92
+36% +$21.9K ﹤0.01% 1178
2024
Q1 		$69K Hold
259
– – ﹤0.01% 1340
2023
Q4 		$60K Sell
259
-37
-13% -$6.47K ﹤0.01% 1389
2023
Q3 		$43K Buy
+296
New +$55.7K ﹤0.01% 1568

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's MDGL Position: Q1 2026 in Review

KBC Group increased its Madrigal Pharmaceuticals (MDGL) stake by 17% in Q1 2026, buying an estimated $33.4K and bringing the position to 484 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

KBC Group first reported a position in MDGL in Q3 2023 and has held it in 11 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • KBC Group held 484 shares of Madrigal Pharmaceuticals worth $253K as of Q1 2026.
  • KBC Group bought 70 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $33.4K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #906 holding.
  • KBC Group first reported a position in Madrigal Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.